Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2004

View Archived Issues

Bifunctional drug inhibits beta-amyloid aggregation in vitro

Treatment with LXR agonist T-0901317 affects APP processing, ABCA1 upregulation and Abeta secretion

New data on mild cognitive impairment and its relationship with Alzheimer's disease

Dual TNF-alpha and COX-2 inhibitor for the treatment of inflammatory diseases

Antitumor colchicine derivatives prepared at Aventis

Novel HDAC inhibitors in early development at Roche

Ecgonine and ecgonidine analogues and their use reported by Entropin

New oxazolidinones with antiviral activity identified at Bayer

Novel MCH antagonists and their use in obesity and related disorders

New monoamine reuptake inhibitors discovered by Lilly researchers

Acorda Therapeutics acquires Zanaflex rights from Elan

New South African phase II study for Hemopure in trauma patients

Celera Diagnostics and Merck & Co. enter Alzheimer's collaboration

GenVec and NIAID advance HIV vaccine into clinical testing

ISTA launches Istalol for glaucoma

Enrollment completed in phase II LymphoStat-B studies in RA and SLE

Gemzar combination therapy receives European approvals for ovarian cancer

Chromos Molecular Systems completes acquisition of CellExSys

Positive outcome of Dynavax phase IIa asthma challenge study

Forbes Medi-Tech adds cholesterol absorption inhibitors to pipeline

Preliminary 30-month data show benefit of Raptiva in psoriasis

Further positive phase I/II data for NX-1207 in BPH

Pramipexole and levodopa confer benefit to Parkinson's disease patients

NY-ESO-1/ISCOMATRIX cancer vaccine shows promise in clinical study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...